PMID: 11762817Jan 5, 2002Paper

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma

Annals of Oncology : Official Journal of the European Society for Medical Oncology
D MachoverC Jasmin


Dexamethasone. cytarabine (ara-C), and cisplatin (DHAP) can be used effectively to treat patients with non-Hodgkin's lymphoma (NHL). We hypothesized that substitution of cisplatin by oxaliplatin (L-OHP) could result in less toxicity and greater efficacy. L-OHP is active in patients with lymphoma. It produces mild myelosuppression and is devoid of renal toxicity. We report on a phase II study of dexamethasone, high-dose ara-C, and L-OHP (DHAOx) used to treat patients with NHL who were previously treated with chemotherapy. Fifteen patients were given DHAOx. They had failed to achieve a CR with initial chemotherapy or had recurrent disease. DHAOx consisted of dexamethasone, 40 mg/day (days 1 to 4): L-OHP, 130 mg/m2 (day 1); and ara-C, 2,000 mg/m2 every 12 h (day 2). Treatment was repeated every 21 days. Patients received a median of four courses of DHAOx. Myelosuppression and transient sensory peripheral neuropathy were the most prominent toxic effects. Serum creatinine levels did not increase in patients with normal renal function, nor in patients who had renal impairment before DHAOx. The median follow-up time from the start of DHAOx treatment was 17 months. Eight patients (53%) achieved a CR, and three patients (20%) had a PR. ...Continue Reading


Jul 26, 2006·Acta Oncologica·Alberto MuñozGuillermo López-Vivanco
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Stefan WöhrerMarkus Raderer
Feb 12, 2009·Hematological Oncology·Davide Rossi, Gianluca Gaidano
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus RadererChristoph C Zielinski
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Apostolia M TsimberidouMichael J Keating
Oct 29, 2005·Leukemia & Lymphoma·Lapo AlinariPier Luigi Zinzani
Apr 30, 2009·Cancer·Apostolia-Maria Tsimberidou, Michael J Keating
Jul 12, 2002·Hematological Oncology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre
Ozkan KanatMustafa Ozturk
Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
W S WangP M Chen
© 2022 Meta ULC. All rights reserved